Complications and medication use in the participants
| Impaired awareness of hypoglycemia | P value | ||
| Absent | Present | ||
| n=434 | n=75 | ||
| Self-reported severe hypoglycemia in the past 12 months, n (%) | 136 (31.3) | 58 (77.3) | <0.001 |
| Self-reported severe hypoglycemia requiring medical intervention, n (%) | 19 (4.4) | 22 (29.3) | <0.001 |
| Hypertension, n (%) | 59 (13.6) | 20 (26.7) | 0.004 |
| Any microvascular complication, n (%) | 198 (45.6) | 51 (68.0) | <0.001 |
| Microalbuminuria, n (%) | 66 (15.6) | 15 (20.0) | 0.346 |
| Macroalbuminuria, n (%) | 9 (2.1) | 0 (0.0) | 0.202 |
| Retinopathy, n (%) | 113 (26.0) | 27 (36.5) | 0.063 |
| Neuropathy self-reported, n (%) | 106 (24.4) | 27 (36.0) | 0.035 |
| Macrovascular complications, n (%) | 20 (4.6) | 9 (12.0) | 0.011 |
| Angina pectoris, n (%) | 6 (1.4) | 0 (0.0) | 0.306 |
| MI, n (%) | 7 (1.6) | 5 (6.7) | 0.008 |
| PTCA, n (%) | 6 (1.4) | 5 (6.4) | 0.004 |
| CABG, n (%) | 5 (1.2) | 4 (5.3) | 0.011 |
| TIA/CVA, n (%) | 7 (1.6) | 3 (4.0) | 0.169 |
| Antihypertensive drugs, n (%) | 90 (20.7) | 27 (36.0) | 0.004 |
| Beta-blockers, n (%) | 20 (4.6) | 7 (9.3) | 0.092 |
| Diuretics, n (%) | 27 (6.2) | 14 (18.7) | <0.001 |
| Calcium antagonists, n (%) | 20 (4.6) | 5 (6.7) | 0.446 |
| RAAS blockers, n (%) | 71 (16.4) | 20 (26.7) | 0.031 |
| Cholesterol-lowering drugs, n (%) | 95 (21.9) | 28 (37.3) | 0.004 |
| Antiplatelet agents, n (%) | 23 (5.3) | 9 (12.0) | 0.027 |
| Antidepressants, n (%) | 21 (4.8) | 8 (10.7) | 0.044 |
Data are presented as mean±SD, median (IQR) or n (%).
CABG, coronary artery bypass grafting; CVA, cerebrovascular accident; MI, myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty; RAAS, renin-angiotensin-aldosterone system; TIA, transient ischemic attack.